After spending the past six months at a nearly perfect four-star ranking, Novartis
Novartis is coming off a stellar first quarter, when earnings rose 49% and the top line increased 25%, and its strong fundamentals and growing pipeline of drugs make many CAPS members bullish on the stock. It has been expanding its opportunities through a recently signed deal with Array BioPharma
Investors have also gained some more confidence with good news about progress in Novartis' pipeline. Organ rejection drug Zortress recently gained approval from the Food and Drug Administration, and the company reported that Afinitor met its late-stage study goals as a treatment for pancreatic cancer. Novartis looks to file for regulatory approval worldwide for the new use this year: Afinitor is already approved for kidney cancer patients who already tried Pfizer's
Do you think Novartis deserves its improved status? Add your thoughts in the comments box below, or head over to CAPS to rate the company and check out all the information and opinions the community offers, absolutely free.